Age-associated microenvironmental changes highlight the role of PDGF-C in ER + breast cancer metastatic relapse.
Frances K TurrellRebecca OrhaNaomi J GuppyAndrea GillespieMatthew GuelbertChris StarlingSyed HaiderClare M IsackePublished in: Nature cancer (2023)
Patients with estrogen receptor (ER)-positive breast cancer are at risk of metastatic relapse for decades after primary tumor resection and treatment, a consequence of dormant disseminated tumor cells (DTCs) reawakening at secondary sites. Here we use syngeneic ER + mouse models in which DTCs display a dormant phenotype in young mice but accelerated metastatic outgrowth in an aged or fibrotic microenvironment. In young mice, low-level Pdgfc expression by ER + DTCs is required for their maintenance in secondary sites but is insufficient to support development of macrometastases. By contrast, the platelet-derived growth factor (PDGF)-C hi environment of aging or fibrotic lungs promotes DTC proliferation and upregulates tumor cell Pdgfc expression stimulating further stromal activation, events that can be blocked by pharmacological inhibition of PDGFRα or with a PDGF-C-blocking antibody. These results highlight the role of the changing microenvironment in regulating DTC outgrowth and the opportunity to target PDGF-C signaling to limit metastatic relapse in ER + breast cancer.
Keyphrases
- estrogen receptor
- growth factor
- squamous cell carcinoma
- small cell lung cancer
- endoplasmic reticulum
- smooth muscle
- poor prognosis
- vascular smooth muscle cells
- positive breast cancer
- breast cancer cells
- stem cells
- magnetic resonance
- free survival
- systemic sclerosis
- idiopathic pulmonary fibrosis
- mouse model
- long non coding rna
- metabolic syndrome
- magnetic resonance imaging
- cell therapy
- angiotensin ii
- type diabetes
- contrast enhanced
- wild type
- smoking cessation
- breast cancer risk